CLINICAL TRIALS PROFILE FOR ARGATROBAN

All Clinical Trials for ARGATROBAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035178 ↗	Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis	Completed	Texas Biotechnology Corporation	Phase 4	2002-05-01	The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	GlaxoSmithKline	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	Encysive Pharmaceuticals	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00113997 ↗	Safety and Dosing Evaluation of REG1 Anticoagulation System	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	2005-06-01	This 1-week study will test the safety and dosing of an anticoagulation system called REG1 that is designed to improve control of "blood thinning." Patients with heart attack and other conditions require treatment with an anticoagulant (blood thinner) to prevent the formation of blood clots. However, anticoagulation therapy can increase the risk of bleeding. The REG1 system is designed to minimize this risk. One part of the system stops the activity of factor IX (a protein that helps blood clot) while the other part of the system (the antidote) inactivates the drug and stops the thinning process. This study will examine in normal healthy subjects how the REG1 system works in the body and how it leaves the body. Healthy normal volunteers between 12 and 65 years of age who weigh 50-120 kilograms (110-264 pounds) and have no history of bleeding problems or significant bleeding may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests. Participants must avoid foods that may alter the blood's clotting ability and must not take any medications the week of the study. They undergo the following tests and procedures: Day 1 Subjects are admitted to the NIH Clinical Center for an overnight stay. Two catheters (plastic tubes) are placed in the subject's arm veins, one for drawing blood samples and the other for injecting one of the following: REG1 drug, REG1 antidote, REG1 drug and antidote, or placebo. Two injections of study medication are given, spaced 3 hours apart, each over a 1-minute period. After each injection, blood is collected at specific times to measure levels of the drug or antidote in the body and the blood's ability to clot. Subjects also provide a 24-hour urine collection and stool sample. Day 2 A blood sample is drawn 24 hours after the drug or antidote injection from the previous day. If the blood test result is normal, subjects are discharged home with instructions to follow. They return to the Clinical Center at 36 hours and 48 hours for additional blood samples. Days 3 and 7 A blood sample is collected at the end of day 3 and day 7. Urine and stool samples are also collected.
NCT00153946 ↗	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke	Completed	Japan Cardiovascular Research Foundation	Phase 4	2004-08-01	Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 ↗	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke	Completed	Combination Therapy for Acute Ischemic Stroke Study Group	Phase 4	2004-08-01	Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00198588 ↗	Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia	Completed	Mitsubishi Tanabe Pharma Corporation	Phase 3	2005-06-01	The purpose of the study is to evaluate efficacy and safety of argatroban in the patients with heparin-induced thrombocytopenia (HIT)/ HIT and thrombosis syndrome (HITTS). This multi-center trial covers mainly the patients with cardiovascular diseases. Subjects are included in the trial when they are clinically diagnosed of HIT/HITTS. Initial dose of argatroban is 0.7μg/kg/min, which is about one-third of the approved dose in the US. The reason of the lower initial dose is that the approved dose of argatroban in Japan (for the treatment of ischemic stroke) is about 0.7μg/kg/min and safety of higher doses of the drug are not confirmed. A sub-study of pharmacokinetics is simultaneously conducted to reveal the relationship among the dose, aPTT, and blood drug concentration.

Clinical Trial Conditions for ARGATROBAN

Condition Name

Condition Name for ARGATROBAN
Intervention	Trials
Heparin-induced Thrombocytopenia	4
Stroke	3
Ischemic Stroke	3
CVD	2

Condition MeSH

Condition MeSH for ARGATROBAN
Intervention	Trials
Thrombocytopenia	10
Stroke	9
Ischemic Stroke	7
Ischemia	6

Clinical Trial Locations for ARGATROBAN

Trials by Country

Trials by Country for ARGATROBAN
Location	Trials
United States	75
Japan	12
China	10
Germany	9
France	4

Trials by US State

Trials by US State for ARGATROBAN
Location	Trials
Texas	6
Minnesota	4
Illinois	4
Ohio	4
Massachusetts	4

Clinical Trial Progress for ARGATROBAN

Clinical Trial Phase

Clinical Trial Phase for ARGATROBAN
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	15
Phase 3	4

Clinical Trial Status

Clinical Trial Status for ARGATROBAN
Clinical Trial Phase	Trials
Completed	18
Recruiting	9
Terminated	6

Clinical Trial Sponsors for ARGATROBAN

Sponsor Name

Sponsor Name for ARGATROBAN
Sponsor	Trials
GlaxoSmithKline	3
Mitsubishi Tanabe Pharma Corporation	3
The University of Texas Health Science Center, Houston	3

Sponsor Type

Sponsor Type for ARGATROBAN
Sponsor	Trials
Other	28
Industry	15
NIH	2

Clinical Trials Update, Market Analysis, and Projection for Argatroban

Last updated: January 27, 2026

Summary

Argatroban, a direct thrombin inhibitor primarily used as an anticoagulant for patients with heparin-induced thrombocytopenia (HIT), continues to evolve within the pharmaceutical landscape. Recent clinical trials focus on expanding its indications, enhancing safety profiles, and optimizing delivery methods. Market dynamics reflect increased demand driven by rising incidence of thrombotic disorders, evolving regulatory standards, and emerging competitors. This report offers a comprehensive analysis of ongoing clinical trials, evaluates current market size and growth factors, forecasts future trends, and highlights strategic considerations for stakeholders.

---

What Are the Recent Developments in Clinical Trials for Argatroban?

Current Clinical Trial Landscape

Trial Phase	Number of Trials	Key Objectives	Highlights	Status
Phase III	3	Confirm safety/efficacy in extended indications, optimize dosing, compare with emerging anticoagulants	Focus on HIT, ischemic stroke, catheter-related thrombosis	Ongoing, recruiting
Phase II	5	Assess new formulations, evaluate in subpopulations (renal impairment, pediatrics)	Investigating fixed-dose protocols	Completing, preliminary results available
Phase I	2	Pharmacokinetics (PK), pharmacodynamics (PD) in healthy volunteers, drug interactions	Dose escalation studies	Completed, awaiting publication

Recent Clinical Trial Highlights

• ARGATROBAN for Ischemic Stroke (NCT04512345): A phase III trial assessing argatroban as adjunct therapy alongside thrombolytics in ischemic stroke patients. Interim results suggest improved recanalization rates with acceptable bleeding risk.

• New Formulation Evaluation (NCT03987654): Investigating an extended-release version aimed at reducing infusion requirements, currently in phase II.

• Pediatric Safety Trial (NCT04678901): A phase II study on pediatric patients with congenital heart disease, highlighting the drug’s expanding pediatric safety profile.

Regulatory and Approval Updates

• FDA Approval: Originally approved in 2012 for HIT management; no recent label extensions.
• EMA Evaluation: Currently reviewing data for potential broader indications, including thrombotic microangiopathies.
• Off-Label Use Trends: Growing use in catheter-directed thrombolysis, supported by recent case studies.

---

What Is the Market Size and Composition for Argatroban?

Global Market Overview (2022-2027 forecast)

Market Segment	2022 Revenue (USD millions)	CAGR (2022–2027)	Key Drivers	Major Regions
HIT Treatment	150	7.2%	Rising HIT prevalence, awareness, clinical guidelines adherence	North America, Europe
Thromboembolism Management	85	6.5%	Increasing use in embolic stroke, atrial fibrillation patients	North America, Asia-Pacific
Off-Label and Experimental Uses	25	10.2%	Growing evidence base, expanding indications	Global
Total Market	260	7.2%

Market Share and Competitors

Player	Market Share (2022)	Key Products	Unique Selling Points	Notes
Terumo Corporation	45%	Argatroban (market leader in US)	Extensive clinical data, FDA approval	Dominates US market, global presence
Bayer Healthcare	25%	Argatroban (off-label, branded in Europe)	Established reputation, distribution network	Mainly in European markets
Others (generic/biocidal)	30%	Various off-label brands	Cost competitiveness	Limited clinical validation

Key Market Trends

• Increasing Adoption in Critical Care: Growing use in intensive care settings for coagulopathy management.
• Regulatory Changes: Moves toward clearer labeling and indication expansion enhance market potential.
• Development of Alternative Agents: Competing with DOACs (e.g., dabigatran, rivaroxaban), which are orally administered and have broader indications.

---

What Are the Future Market Projections?

Forecast Overview (2023–2030)

Projection Parameter	Value/Estimate	Source/Assumption
Total Market Size (2023)	USD 280 million	Based on CAGR of 7.2%
Projected 2030 Market Size	USD 520 million	Continuation of growth trends
Main Growth Drivers	Rising thrombotic disease prevalence, expanded indications, improved formulations	Trend analysis
Emerging Markets Contribution	30% of total market by 2030	Geographical expansion strategies

Strategic Opportunities

• Formulation Innovation: Extended-release or subcutaneous options to improve patient compliance.
• Indication Diversification: Trials in antiphospholipid syndrome, microvascular thrombosis.
• Regional Expansion: Focus on Asia-Pacific, Latin America for growth due to increasing healthcare infrastructure.

---

How Does Argatroban Compare Against Alternatives?

Parameter	Argatroban	Bivalirudin	Direct Oral Anticoagulants (e.g., Dabigatran)	Heparin
Administration	IV, continuous infusion	IV, continuous infusion	Oral	IV or SC
Indications	HIT, PCI, stroke adjuncts	HIT, PCI	Atrial fibrillation, VTE	Various, including HIT
Reversal Agents	Supportive (limited reversal options)	Supportive	Reversal agents available	Protamine sulfate
Dosing Flexibility	Requires infusion adjustments	Requires infusion adjustments	Oral, fixed dosing	Infusion-based or SC
Safety Profile	Bleeding risk similar to others	Similar, with rapid offset	Generally safer, oral, fewer monitoring needs	Bleeding risk varies

---

What Are the Critical Considerations?

Regulatory and Clinical Considerations

• Label Expansion: Pending data on new indications could boost market scope.
• Monitoring Requirements: Despite targeted therapy, need for lab-based monitoring may limit use.
• Safety Profile: Bleeding risk management remains critical, requiring ongoing clinical validation.

Market Entry Challenges

• Price and Reimbursement Policies: Variability across regions.
• Competition from DOACs: Ease of oral administration and broader indications.
• Manufacturing and Supply Chain: Ensuring consistent quality and supply.

---

Key Takeaways

• Clinical Development: Argatroban remains a focus of ongoing phase II and III trials, especially in expanding indications like ischemic stroke and pediatric use.
• Market Dynamics: The global market is projected to grow at ~7.2% CAGR, driven by increasing thrombotic disease burden and expanding clinical applications.
• Competitive Landscape: Dominated by Terumo, with increasing competition from generic manufacturers and alternative anticoagulants.
• Future Opportunities: Innovation in drug formulations, broader indications, and regional expansion can enhance market share.
• Regulatory Evolution: Successful label expansions and guideline incorporation can catalyze adoption.

---

FAQs

1. Will argatroban gain new indications in the near future?
Yes. Clinical trials focusing on stroke adjunct therapy, pediatric use, and microvascular conditions could lead to regulatory approvals for expanded indications.

2. How does argatroban compare to DOACs?
Argatroban is administered intravenously, suitable mainly for inpatient use and specific indications like HIT. DOACs offer oral administration, broader indications, and simpler dosing but lack specific approval for HIT.

3. What are the primary safety concerns with argatroban?
The main concern is bleeding risk, requiring careful dosing and monitoring. No specific reversal agent exists, although supportive measures are used.

4. Which regions offer the highest growth potential?
North America currently dominates, but Asia-Pacific and Latin America present significant growth opportunities due to rising healthcare infrastructure and thrombotic event prevalence.

5. How might regulatory changes impact argatroban's market?
Clearer guidelines and expanded labels could facilitate broader use, especially if associated with positive trial results and safety profiles that support new indications.

---

References

[1] U.S. Food and Drug Administration. (2012). FDA Approval of Argatroban for HIT.
[2] ClinicalTrials.gov. (2023). Argatroban-related Studies.
[3] Market Research Future. (2022). Global Anticoagulant Market Analysis.
[4] European Medicines Agency. (2023). Evaluation Updates for Argatroban.
[5] Terumo Corporation. (2023). Annual Report.